Levetiracetam Actavis

Ülke: Yeni Zelanda

Dil: İngilizce

Kaynak: Medsafe (Medicines Safety Authority)

Aktif bileşen:

Levetiracetam 500mg;  

Mevcut itibaren:

Teva Pharma (New Zealand) Limited

INN (International Adı):

Levetiracetam 500 mg

Doz:

500 mg

Farmasötik formu:

Film coated tablet

Kompozisyon:

Active: Levetiracetam 500mg   Excipient: Colloidal silicon dioxide Crospovidone Magnesium stearate Opadry yellow 85F32371 Povidone

Reçete türü:

Prescription

Tarafından üretildi:

Neuland Laboratories Limited

Terapötik endikasyonlar:

Use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. Monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. Add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).

Ürün özeti:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with LDPE screw cap and tamper evident - 100 tablets - 36 months from date of manufacture stored at or below 25°C

Yetkilendirme tarihi:

2015-01-22